| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/05/2010 | US7807143 treating or delaying the onset of multiple sclerosis using enteric Alpha-melanocyte stimulating hormone (MSH); soluble immune response suppressor (SIRS) |
| 10/05/2010 | US7807142 comprising interleukin-2 (IL-2); using an amino acid base sufficient to decrease aggregate formation of the polypeptide during storage of the composition, and a buffering agent ; mixture with amino acid and buffer |
| 10/05/2010 | CA2509605C Alpha-2-delta ligand to treat lower urinary tract symptoms |
| 10/05/2010 | CA2506803C Functional domain and associated molecule of dock2 essentially required in lymphocyte migration |
| 10/05/2010 | CA2455167C New pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| 10/05/2010 | CA2436233C Perylenequinones for use with immunotherapy agents |
| 10/05/2010 | CA2391161C Pharmaceutical combinations comprising a p2t receptor antagonist and an anti-thrombotic agent |
| 10/05/2010 | CA2367138C Anti-inflammatory uses of manzamines |
| 10/05/2010 | CA2362930C Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use |
| 09/30/2010 | WO2010111511A1 Binary and tertiary galvanic particulates and methods of manufacturing and use thereof |
| 09/30/2010 | WO2010111485A1 Compositions for stimulation of mammalian innate immune resistance to pathogens |
| 09/30/2010 | WO2010111172A1 Methods of treatment using combination therapy |
| 09/30/2010 | WO2010111136A2 Aliskiren modulation of neurogenesis |
| 09/30/2010 | WO2010110428A1 Prophylactic and/or therapeutic agent for pruritus |
| 09/30/2010 | WO2010110374A1 Agent for enhancing hypoglycemic activity |
| 09/30/2010 | WO2010110268A1 Pharmaceutical agent for preventing cell death |
| 09/30/2010 | WO2010109706A1 Therapeutic agent for cancer having reduced sensitivity to molecular targeted drug, and pharmaceutical composition for enhancing sensitivity to molecular targeted drug |
| 09/30/2010 | WO2010078449A3 Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| 09/30/2010 | WO2010068714A3 Deuterated compounds as hepatitis c virus (hcv) inhibitors |
| 09/30/2010 | US20100249746 Drug delivery system for accelerated subcutaneous absorption |
| 09/30/2010 | US20100249217 Modulators of pharmacological agents |
| 09/30/2010 | US20100249160 Cancer Treatment Method |
| 09/30/2010 | US20100249134 Use of Beta-Adrenoceptor Antagonists for the Manufacture of a Medicament for the Treatment of Disorders of the Outer Retina |
| 09/30/2010 | US20100249090 Neurotherapeutic composition and method therefor |
| 09/30/2010 | US20100249034 Gfralpha3 and its uses |
| 09/30/2010 | US20100248240 Gene and protein relating to hepatocellular carcinoma and methods of use thereof |
| 09/30/2010 | US20100247610 Gastric retained gabapentin dosage form |
| 09/30/2010 | US20100247557 Immunostimulant Composition Comprising At Least One Toll-Like Receptor 7 Or Toll-Like Receptor 8 Agonist And A Toll-Like Receptor 4 Agonist |
| 09/30/2010 | US20100247454 Compositions for elastogenesis and connective tissue treatment |
| 09/30/2010 | CA2756669A1 Binary and tertiary galvanic particulates and methods of manufacturing and use thereof |
| 09/30/2010 | CA2756412A1 Compositions for stimulation of mammalian innate immune resistance to pathogens |
| 09/30/2010 | CA2755976A1 Methods of treatment using combination therapy |
| 09/29/2010 | EP2233154A1 Skin external preparation |
| 09/29/2010 | EP2233147A1 Salt solution for colon cleansing |
| 09/29/2010 | EP2233136A1 Use of HPPD Inhibitors in the Treatment of Depression and/or Withdrawal Symptoms Associated with Addictive Drugs |
| 09/29/2010 | EP2231138A1 Oral pharmaceutical suspension comprising paracetamol and ibuprofen |
| 09/29/2010 | EP2231128A1 Method of treating dysglycemia and glucose excursions |
| 09/29/2010 | EP1615698B1 New amide derivatives and pharmaceutical use thereof |
| 09/29/2010 | EP1578412B1 Pharmaceutical compositions and method of treating parkinson's disease |
| 09/29/2010 | EP1534695B1 Tyrosine kinase inhibitors |
| 09/29/2010 | EP1450847B1 APO2 ligand/ TRAIL formulations and uses thereof |
| 09/29/2010 | EP1446136B1 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 09/29/2010 | EP1095274B1 Trifunctional reagent for conjugation to a biomolecule |
| 09/29/2010 | CN1984640B Topical antiviral formulations |
| 09/29/2010 | CN1935254B Method for neuregulin treating cardio vascular disease, and composition |
| 09/29/2010 | CN1794974B 药物递送体系 Drug delivery system |
| 09/29/2010 | CN1695740B Composite body of fiber protein adhesive and antibiotics in use for treating infection in deep part, and application |
| 09/29/2010 | CN101848726A Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| 09/29/2010 | CN101848709A Treatment of oral pharyngeal dysphagia |
| 09/29/2010 | CN101843904A Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer |
| 09/29/2010 | CN101843897A Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders |
| 09/29/2010 | CN101843641A Novel adenoviruses, nucleic acids coding therefor, and use thereof |
| 09/29/2010 | CN101843614A Application of metronidazole or its pharmacologically acceptable derivative |
| 09/29/2010 | CN101843581A Multi-portion intra-oral dosage form with organoleptic properties |
| 09/29/2010 | CN101843577A Coating implant using zein as skeleton material and preparation method |
| 09/29/2010 | CN101321539B Novel combination of anticholinergics, glucocorticoid, Beta2-agonist, PDE 4 inhibitors and antileukotrienes for the treatment of inflammatory disease |
| 09/29/2010 | CN101175495B Anti-cancer compound combination |
| 09/28/2010 | USRE41783 Pyrrolo[2,3-D]pyrimidine compounds |
| 09/28/2010 | US7803944 Viral polymerase inhibitors |
| 09/28/2010 | US7803805 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl)-3-oxo-propionitrile mono citrate salt; immunosuppressants, autoimmune diseases, skin disorders, Crohn's disease, antidiabetic agents, anticancer agents, antiarthritic agents |
| 09/28/2010 | US7803780 gene therapy of transferring the CD9 gene for suppressing cardiac hypertrophy or cardiac tachycardia in a patient having a heart disease; viral or non-viral expression vector containing a sequence encoding a CD9 protein |
| 09/28/2010 | US7803776 Combined use of enzyme inhibitors and of pharmaceutical compositions thereof |
| 09/28/2010 | US7803766 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; long-acting action |
| 09/28/2010 | US7803739 Substrates and assays for β-secretase |
| 09/28/2010 | US7803595 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| 09/28/2010 | US7803562 Method for screening human intestinal Npt2B modulatory agents |
| 09/28/2010 | US7803560 Contacting a candidate antagonist with a MCP-1 receptor polypeptide having an amino acid sequence at least 95% homologous to an extracellular domain of a specific sequence, and comparing the binding of MCP-1 to the receptor polypeptide; decreased binding indicates an antagonist |
| 09/28/2010 | US7803546 Method of screening for sensitivity to kinase inhibitor therapy |
| 09/28/2010 | US7803408 Use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium |
| 09/28/2010 | US7803393 Gas-plasma treatment of a substrate of medical implant; living cells coupled to a treated substrate may produce more of a growth factor than living cells coupled to an untreated substrate |
| 09/28/2010 | US7803379 Tumour-specific animal proteins |
| 09/28/2010 | US7803361 Decreasing solid tumor size in a cancer patient by administering an interleukin-2 mutant with reduced vasopermeability activity compared to a wildtype form, and being Arg38Trp, wherein said wildtype form is human IL-2 mutant and the IL-2 mutant is not linked to an antibody. |
| 09/28/2010 | US7803354 Cosmetic and/or dermatological use of a composition comprising at least one oxidation-sensitive hydrophilic active principle stabilized by at least one maleic anhydride copolymer |
| 09/28/2010 | CA2493765C Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 09/28/2010 | CA2474430C A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction |
| 09/28/2010 | CA2464152C Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract |
| 09/28/2010 | CA2450915C Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure |
| 09/28/2010 | CA2449952C Medicinal composition |
| 09/28/2010 | CA2407633C Method and compositions for inhibiting arteriosclerosis |
| 09/28/2010 | CA2394090C Oligosaccharide mixture |
| 09/28/2010 | CA2308201C Use of anti-fungal agents for the treatment of fungus-induced mucositis |
| 09/27/2010 | CA2660622A1 Rig-i mutations and uses thereof in diagnostic and therapeutic virus-dependent immune applications |
| 09/23/2010 | WO2010107968A1 Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
| 09/23/2010 | WO2010107404A1 Stable pharmaceutical combinations |
| 09/23/2010 | WO2010106988A1 Amide derivative |
| 09/23/2010 | WO2010106502A1 A novel dermaceutical cream made using sodium fusidate, clotrimazole and clobetasol propionate, a process to make the same and a method of treatment using it |
| 09/23/2010 | WO2010106465A1 A dermaceutical cream made using sodium fusidate, clotrimazole and fluticasone propionate |
| 09/23/2010 | WO2010106459A1 A dermaceutical cream made using sodium fusidate, clotrimazole and mometasone furoate |
| 09/23/2010 | WO2010106355A1 Compound for the treatment of tuberculosis |
| 09/23/2010 | WO2010106135A1 Combined use for the treatment of ovarian carcinoma |
| 09/23/2010 | WO2010081662A3 Methods for identifying patients who will respond well to cancer treatment |
| 09/23/2010 | US20100240866 Modified gherlin peptides |
| 09/23/2010 | US20100240758 External preparation for percutaneous administration containing nonsteroidal anti-inflammatory analgesic |
| 09/23/2010 | US20100240744 Methods for the treatment of dementia based on apo e genotype |
| 09/23/2010 | US20100240742 Anti-angiogenic compositions and methods of use |
| 09/23/2010 | US20100240721 desoxyepothilone A and B; Fludelone; anticarcinogenic agents; drug resistance; water solubility for formulability; industrial scale; cytotoxic or growth inhibitory effects on CAG myeloma cells lines; ability to polymerize tubulin; minimum toxicity; stabilizing microtubules |
| 09/23/2010 | US20100240650 Substituted pyrrolines as kinase inhibitors |
| 09/23/2010 | US20100240633 Cancer treatment methods |
| 09/23/2010 | US20100240602 Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
| 09/23/2010 | US20100239670 Topical Composition Method for Treating Urinary Stress Incontinence |